Laurus Labs Ltd's Q4FY25 Quarter Results
- 25 Apr 2025
Result Summary
- Laurus Labs Ltd reported a 2.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.5%.
- Its expenses for the quarter were up by 4.4% QoQ and 9.3% YoY.
- The net profit decreased 19.3% QoQ and decreased 28.7% YoY.
- The earnings per share (EPS) of Laurus Labs Ltd stood at 1.4 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1458.20 | 1424.47 | 1382.61 | 2.4% | 5.5% |
Total Expenses | 1350.93 | 1293.79 | 1235.47 | 4.4% | 9.3% |
Profit Before Tax | 107.27 | 130.68 | 147.14 | -17.9% | -27.1% |
Tax | 31.95 | 40.07 | 39.90 | -20.3% | -19.9% |
Profit After Tax | 75.02 | 92.94 | 105.27 | -19.3% | -28.7% |
Earnings Per Share | 1.40 | 1.70 | 1.90 | -17.6% | -26.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Laurus Labs Ltd is a well-regarded pharmaceutical company primarily engaged in the development, manufacturing, and sale of generic active pharmaceutical ingredients (APIs) and finished dosage forms. The company has established itself as a significant player in the pharmaceuticals industry, with its offerings spanning across antiretrovirals, hepatitis C, and oncology segments. Based in India, Laurus Labs has consistently expanded its product portfolio to cater to a diverse global clientele. Recent major developments about the company are not available from the data provided.
Revenue
During Q4FY25, Laurus Labs Ltd recorded a total income of ₹1458.20 crores, marking a 2.4% increase from the previous quarter (Q3FY25) where the income was ₹1424.47 crores. The year-over-year comparison shows a 5.5% increase from Q4FY24, where the total income was ₹1382.61 crores. This upward trend in revenue indicates solid performance over both the quarterly and annual periods, reflecting the company's ability to maintain growth amid the competitive landscape of the pharmaceutical industry.
Profitability
In terms of profitability, Laurus Labs Ltd experienced a decline in its profit metrics during Q4FY25. The profit before tax stood at ₹107.27 crores, showing a decrease of 17.9% from Q3FY25 and a 27.1% drop from Q4FY24. The tax expense for Q4FY25 was ₹31.95 crores, representing a 20.3% decrease from the previous quarter and a 19.9% decrease from the same quarter in the prior year. Consequently, the profit after tax for Q4FY25 was ₹75.02 crores, reflecting a 19.3% decline quarter-over-quarter and a 28.7% decrease year-over-year. Earnings per share for the quarter were ₹1.40, down from ₹1.70 in Q3FY25 and ₹1.90 in Q4FY24, indicating a negative trend in shareholder returns compared to previous periods.
Operating Metrics
The total expenses for Laurus Labs Ltd in Q4FY25 amounted to ₹1350.93 crores, an increase of 4.4% from Q3FY25, where expenses were ₹1293.79 crores. Compared to the same quarter in the previous year, total expenses rose by 9.3% from ₹1235.47 crores. This rise in expenses over both the quarterly and annual periods is a critical area for operational analysis. Despite the increase in revenues, the higher rise in expenses contributed to the decline in profitability margins for the quarter. Key financial ratios, such as the price-to-earnings (P/E) ratio, debt-to-equity ratio, and current ratio, are not calculable from the provided data and thus are not included in this report.
